The specific aims of this study are to 1) evaluate GFR in cystic fibrosis patients at baseline and after 6 months of ibuprofen (IBU) therapy; 2) to evaluate tobramycin pharmacokinetics in CF patients at baseline and after six months of IBU therapy; and 3) to compare baseline GFR in CF patients vs historic age-matched controls. The hypotheses are: 1) high dose IBU therapy causes a significant decrease in GFR in CF patients after six months of therapy; 2) clearance of tobramycin is significantly decreased in CF patients after initiation of high dose IBU therapy when compared to baseline values; 3) baseline GFR in patients with CF is not different from healthy age-matched control patients. Preliminary results show that over a 6-month period, renal function did not appear to worsen with high dose Ibuprofen therapy. A larger sample and longer treatment period are needed to ensure the validity of these results. These results do not preclude occasional severe nephrotoxicity from Ibuprofen.
Showing the most recent 10 out of 753 publications